Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma (Q33905047)

29 July 2017

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma (English)

1 reference

29 July 2017

0 references

Rampling R

1

1 reference

29 July 2017

Cruickshank G

2

1 reference

29 July 2017

Papanastassiou V

3

1 reference

29 July 2017

Nicoll J

4

1 reference

29 July 2017

Hadley D

5

1 reference

29 July 2017

Brennan D

6

1 reference

29 July 2017

Petty R

7

1 reference

29 July 2017

MacLean A

8

1 reference

29 July 2017

Harland J

9

1 reference

29 July 2017

McKie E

10

1 reference

29 July 2017

Mabbs R

11

1 reference

29 July 2017

Brown M

12

1 reference

29 July 2017

1 May 2000

1 reference

29 July 2017

1 reference

29 July 2017

7

1 reference

29 July 2017

859-866

1 reference

29 July 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3301184

29 July 2017

0 references

cites work

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Virus treatment questioned after gene therapy death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

Stereotaxic interstitial irradiation of malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

inferred from DOI database lookup

7 January 2021

based on heuristic

Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

inferred from DOI database lookup

7 January 2021

based on heuristic

Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301184

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3301184

1 reference

29 July 2017

1 reference